Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) Research & Development (2016 - 2024)

Rockwell Medical filings provide 15 years of Research & Development readings, the most recent being $1000.0 for Q4 2024.

  • On a quarterly basis, Research & Development fell 99.38% to $1000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $1000.0, a 99.44% decrease, with the full-year FY2024 number at $19000.0, down 98.27% from a year prior.
  • Research & Development hit $1000.0 in Q4 2024 for Rockwell Medical, down from $18000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.4 million in Q2 2021 to a low of $1000.0 in Q4 2024.
  • Median Research & Development over the past 5 years was $1.1 million (2021), compared with a mean of $1.0 million.
  • Biggest five-year swings in Research & Development: surged 266.4% in 2020 and later tumbled 99.38% in 2024.
  • Rockwell Medical's Research & Development stood at $1.9 million in 2020, then dropped by 27.19% to $1.4 million in 2021, then crashed by 88.78% to $156000.0 in 2022, then grew by 3.21% to $161000.0 in 2023, then tumbled by 99.38% to $1000.0 in 2024.
  • The last three reported values for Research & Development were $1000.0 (Q4 2024), $18000.0 (Q1 2024), and $161000.0 (Q4 2023) per Business Quant data.